Brief: Abogen Announces Licensing And Option Agreement With Novartis
02/10/2026 08:02
BRIEF-Abogen Announces Licensing And Option Agreement With Novartis Oct 2 (Reuters) - ABOGEN:
ABOGEN ANNOUNCES LICENSING AND OPTION AGREEMENT WITH NOVARTIS TO ADVANCE MRNA-ENCODED T-CELL ENGAGER AND OTHER POTENTIAL RNA PROGRAMS
ABOGEN - ABOGEN IS ELIGIBLE TO RECEIVE UP TO APPROXIMATELY USD 7.2 BILLION IN POTENTIAL MILESTONE PAYMENTS
ABOGEN - ABOGEN WILL RECEIVE AN UPFRONT PAYMENT OF USD 575 MILLION
Source text: ID:nPn8P923Ya
Further company coverage: NOVN.S
((Reuters.briefs@thomsonreuters.com;))
Recent news on Novartis AG
See all newsNovartis AG expected to post earnings of $2.27 a share - Earnings Preview
AbbVie's skin disease drug reduces lesions in trial, company eyes weight-loss combination (updated)
AbbVie's skin disease drug reduces lesions in trial, company eyes weight-loss combination
Brief: Novartis Receives European Commission Approval For Cosentyx
Insight: How cheap Chinese antibiotics threaten Europe's last major penicillin plant